Romosozumab is the newest pharmaceutical intervention for the bone remodeling cycle. Romosozumab is a monoclonal antibody that binds to sclerostin, allowing Wnt ligands to activate the canonical pathway, stimulate bone formation, and inhibit bone resorption (Figure ). The disadvantage is that romosozumab is associated with more undesirable side effects than bisphosphonates including increased risk of adverse